CALM2

CALM2 encodes one of the cell's calmodulin proteins and functions chiefly as a Ca2+-dependent regulator of cardiac ion channel inactivation, with pathogenic missense variants causing calmodulinopathy-associated arrhythmia (PMID:26969752, PMID:28335032). In cardiomyocytes, CALM2 controls inactivation of the L-type calcium channel (CaV1.2): variants such as E141G reduce Ca2+ binding affinity ~11-fold and produce a functionally dominant loss of CaV1.2 inactivation with mild accentuation of NaV1.5 late current, while N98S exerts dominant-negative suppression of L-type channel inactivation that prolongs action potential duration (PMID:26969752, PMID:28335032). The causal role of CALM2 in this electrophysiological phenotype is established by allele-specific CRISPR knockout of the mutant allele, which rescued channel inactivation and normalized action potential duration, and by suppression-and-replacement gene therapy that shortened the pathologically prolonged action potential of D130G cardiomyocytes (PMID:28335032, PMID:39069900). CALM2 is the largest of the three CALM genes by contribution to ventricular calmodulin protein, accounting for ~44% of calmodulin translation in the left ventricle, consistent with the intermediate cardiac event rate of its variant carriers (PMID:41846582). Beyond the heart, CALM2 promotes survival and proliferation in cancer contexts: its knockdown suppresses Akt signaling to activate a FoxO3a/Puma pro-apoptotic axis in gastric cancer cells (PMID:36460225). Promoter analysis defined a TATA-like element and a 5'UTR requirement for full CALM2 transcriptional activity (PMID:9681195).

1. 1998 Medium

   Established the transcriptional architecture of CALM2 relative to the other calmodulin genes, addressing how a triplicated gene set is differentially expressed.

   Evidence Genomic sequencing, luciferase promoter reporter and deletion assays, and run-on transcription in human teratoma cells

   PMID:9681195

   Open questions at the time

   • Does not link promoter usage to tissue-specific calmodulin function
   • Regulatory factors binding the TATA-like element not identified
2. 2016 Medium

   Showed how a CALM2 missense variant translates into channel dysfunction, defining reduced Ca2+ affinity and loss of CaV1.2 inactivation as the biophysical lesion.

   Evidence Ca2+ binding affinity assay and patch-clamp of CaV1.2 and NaV1.5 with E141G mutant protein

   PMID:26969752

   Open questions at the time

   • Single-lab heterologous characterization
   • No effect on RyR2 leaves the relative channel selectivity of CALM2 incompletely mapped
3. 2017 High

   Demonstrated causality in a human cellular context: the mutant CALM2 allele is necessary and sufficient for the arrhythmogenic phenotype, since removing it rescues channel function.

   Evidence Patient-derived hiPSC-cardiomyocytes with N98S, patch-clamp of action potentials and LTCC currents, allele-specific CRISPR-Cas9 knockout

   PMID:28335032

   Open questions at the time

   • Mechanism of dominant-negative interference among co-expressed wild-type calmodulin not resolved
   • In vivo cardiac validation absent
4. 2021 Low

   Extended CALM2 function beyond the heart, implicating it in tumor cell proliferation and invasion via an E2F5 transcriptional program.

   Evidence siRNA knockdown in HCC cells, transcriptomic profiling, functional assays, and in vivo tumor formation

   PMID:33788723

   Open questions at the time

   • No direct biochemical link between CALM2 and E2F5 shown
   • Limited mechanistic follow-up on the 154 dysregulated genes
5. 2022 Medium

   Defined a survival-signaling role for CALM2 in cancer, placing it upstream of an Akt/FoxO3a/Puma apoptotic decision.

   Evidence siRNA knockdown in HER2-amplified gastric cancer cells, Western blot pathway analysis, caspase assay, and FoxO3a/Puma epistasis

   PMID:36460225

   Open questions at the time

   • Direct molecular target of CALM2 in the Akt pathway not identified
   • Single-lab, single tumor context
6. 2024 Medium

   Advanced a therapeutic strategy by showing that knockdown plus calmodulin replacement corrects the arrhythmic phenotype, confirming that lowering mutant CALM2 dosage is sufficient to restore function.

   Evidence iPSC-cardiomyocytes with D130G, voltage-dye APD90 measurement, and dual-component shRNA suppression-and-replacement construct

   PMID:39069900

   Open questions at the time

   • Durability and in vivo efficacy of the SupRep approach untested
   • Off-target effects of CALM2 knockdown not assessed
7. 2026 Medium

   Quantified CALM2's relative contribution to the ventricular calmodulin pool, providing a dosage rationale for its intermediate variant severity.

   Evidence Ribosome profiling and RNA-seq of left ventricle, gnomAD constraint analysis, and Calmodulinopathy Registry outcomes

   PMID:41846582

   Open questions at the time

   • Correlative rather than manipulative
   • Does not establish whether expression ratios shift under pathological remodeling

• How CALM2's identical protein product achieves gene-specific functional consequences, and whether its non-cardiac signaling roles share a common Ca2+-sensing mechanism, remain open.
• No structural model of mutant calmodulin bound to CaV1.2 in the corpus
• Mechanism distinguishing CALM2 from CALM1/CALM3 beyond expression dosage unknown